Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

Authors

Konstantinos Angelis
Nilay Thakkar (ORCID: https://orcid.org/0000-0002-2846-5796)
Veronica Bainbridge
Andrew R. Tomlinson (ORCID: https://orcid.org/0000-0001-9899-0812)
Rulan Griesel (ORCID: https://orcid.org/0000-0003-3633-2878)
Yash Gandhi (ORCID: https://orcid.org/0000-0001-7637-9617)
Bronagh Shepherd
Carolina Acuipil (ORCID: https://orcid.org/0009-0008-7672-3818)
Darin Brimhall
David Anderson (ORCID: https://orcid.org/0000-0001-9528-1340)
Amy Pierce
Cynthia McCoig
Paul Benn
Mark Baker
Brian Spears
Emma Pinnick

Institutions

ViiV Healthcare (Spain) (ES)
South College (US)
ViiV Healthcare (United Kingdom) (GB)
Glaxosmithkline (Finland) (FI)
Thermo Fisher Scientific (United States) (US)

Publication Details

Journal: Infectious Diseases and Therapy
Published: 2025-04-02
DOI: https://doi.org/10.1007/s40121-025-01129-y
Citations: 2
Primary Topic: HIV/AIDS drug development and treatment
Type: article
Field-Weighted Citation Impact: 2.79

Funders

ViiV Healthcare

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

Konstantinos Angelis, Nilay Thakkar, Veronica Bainbridge, Andrew R. Tomlinson et al.

Apr 2, 2025

2 citations

Infectious Diseases and Therapy

HIV/AIDS drug development and treatment

2.79

article

Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

Konstantinos Angelis, Nilay Thakkar, Veronica Bainbridge, Andrew R. Tomlinson, Rulan Griesel, Yash Gandhi, Bronagh Shepherd, Carolina Acuipil, Darin Brimhall, David Anderson, Amy Pierce, Cynthia McCoig, Paul Benn, Mark Baker, Brian Spears, Emma Pinnick

April 2, 2025article en

2 citations

Abstract

No abstract available for this paper.

Infectious Diseases and TherapyVol. 14(5)

ViiV Healthcare (Spain) (ES), South College (US), ViiV Healthcare (United Kingdom) (GB), Glaxosmithkline (Finland) (FI), Thermo Fisher Scientific (United States) (US)

ViiV Healthcare

Good health and well-being

Openalex Percentile: Top 11%

HIV/AIDS drug development and treatment

2.79

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV — Konstantinos Angelis, Nilay Thakkar, et al. · Infectious Diseases and Therapy (2025) | TGRS Research Map | TGRS